# SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations

Source: https://onco.cc/trials/nct06080776/  
OnCo record `nct06080776` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of SH-1028 tablets in non-small-cell lung cancer, run by Nanjing Sanhome Pharmaceutical, Co., Ltd., now recruiting.

## Summary

SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations is a phase 3 interventional study registered as NCT06080776 by Nanjing Sanhome Pharmaceutical, Co., Ltd., with 242 participants planned, started 2023-05-11 and due to reach its primary completion in 2028-02-01. Interventions recorded: SH-1028 tablets and Placebo SH-1028 tablets.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06080776
- Phase: 3
- Setting: A Phase III, Double-blind, Randomised Study of SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With Sensitizing EGFR Mutations
- Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Enrolled: 242

## Sources

- ClinicalTrials.gov NCT06080776: https://clinicaltrials.gov/study/NCT06080776

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/nct06080776.json